Appointment dossier — Colon Cancer
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Colon Cancer
No studies or cited compounds on file for this cancer yet.
Open recruiting trials (18)
- NCT06530303 · Phase 1 / Phase 2 — Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer (China)
- NCT02595957 — Genomic Services Research Program (United States)
- NCT05713903 — Laparoscopic Versus Open Right Colectomy for Right Colon Cancer (Greece)
- NCT07405931 — Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients (South Korea)
- NCT06598007 · Phase 1 / Phase 2 — A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors (United States)
- NCT05706129 · Phase 1 / Phase 2 — A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors (Australia)
- NCT05296564 · Phase 1 / Phase 2 — Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers (Israel)
- NCT03412877 · Phase 2 — Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer (United States)
- NCT06657144 · Phase 1 — A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors (United States)
- NCT07454642 · Phase 1 — AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors (United States)
- NCT06840886 · Phase 1 — A Study of PHST001 in Advanced Solid Tumors (United States)
- NCT04282044 · Phase 1 — Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies (United States)
- NCT04616495 — Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases (Spain)
- NCT01365169 — Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" (United States)
- NCT06073431 — LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia (United States)
- NCT06394492 · Phase 3 — SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer (China)
- NCT06476184 · Phase 3 — Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery (France)
- NCT06607458 · Phase 2 — Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease (United States)
Most-relevant first: trials that name Colon Cancer, then broader trials you may still qualify for. 1189 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Questions to ask your oncologist
- Of the open trials I found (for example NCT06530303), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?